Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer

Published:2019-05-16 Issue:11 Volume:40 Page:1436-1447
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Zou Ling-jiao,Xiang Qiu-ping,Xue Xiao-qian,Zhang Cheng,Li Chen-chang,Wang Chao,Li Qiu,Wang Rui,Wu Shuang,Zhou Yu-lai,Zhang Yan,Xu Yong

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/s41401-019-0237-5.pdf

Reference50 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

3. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

4. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

5. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;Oncogene;2024-09-13

2. Discovery of an EP300 Inhibitor using Structure-based Virtual Screening andBioactivity Evaluation;Current Pharmaceutical Design;2024-07

3. Association between CACNA1D polymorphisms and hypospadias in a southern Chinese population;Journal of Pediatric Urology;2024-06

4. Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers;Cell Biochemistry and Function;2024-06

5. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;2024-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3